Physician profile
Robert M Adams
NPI 1275693517
$1,647.02
in general payments reported to CMS, 2019-2025
15 companies · $93.49 in 2025
The $93.49 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2021: $152 · 2022: $82.49 · 2023: $463 · 2024: $669 · 2025: $93.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.98 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $503.81 | 2019-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $194.34 | 2022-2024 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $175.41 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $155.80 | 2021-2025 | Ingrezza |
| Corium, LLC | $127.18 | 2023-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.17 | 2023-2025 | Caplyta |
| Tris Pharma INC | $93.30 | 2019-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $90.68 | 2023-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $54.40 | 2021-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $49.78 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $19.34 | 2024 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $13.62 | 2024 | Austedo Xr |
| Neos Therapeutics, LP | $11.47 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.